LONDON, Dec 1 (Reuters) - GlaxoSmithKline's new
injectable asthma drug Nucala has been recommended for use in
Britain's state-run health service in the most severe patients,
after the drugmaker provided further analyses on its use and
made an additional price cut.
Read more
No comments:
Post a Comment